Today Maryland Congressman Chris Van Hollen issued the following statement applauding the Food and Drug Administration's (FDA) plans to move forward on rulemaking that would allow generic drug manufacturers to revise their labels to provide the most accurate, up-to-date information about their products:
"Consumers deserve to know about new risks and side effects of all drugs, and to be equipped to make the best decisions for their families. I'm pleased that the FDA is taking steps to ensure that generic manufacturers have the ability to add or strengthen the warning on their products, like brand name manufacturers do, and urge them to move quickly. We'll keep fighting to make sure American families are informed and kept safe."
Last week, Congressman Van Hollen, along with Senators Patrick Leahy (D-Vt.), Tom Harkin (D-Iowa), Al Franken (D-Minn.), and Congressmen Bruce Braley (D-Iowa), Henry Waxman (D-Calif.), and Matt Cartwright (D-Pa.) sent a letter urging the FDA to expedite consideration of revisions to its existing drug labeling regulations. Last year, he also introduced the Patient Safety and Drug Labeling Improvement Act to addresses this serious problem.